Roche: Stifel maintains 'hold' rating

(CercleFinance.com) - Stifel is maintaining its "hold" recommendation on Roche shares, with an unchanged target price of CHF306.


The analyst reports that, following its Pharmay Day held in London on Monday, Roche is aware of the need to improve its R&D productivity compared with recent years, and has announced a number of measures to this end.

For example, the company intends to introduce a higher level of selectivity before entering phase 3, and to step up the intensity of early-stage development. Roche also intends to "dig deep wherever there is profound innovation to be pursued. "

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.